Terumo (OTCMKTS:TRUMY) Posts Earnings Results, Misses Expectations By $0.01 EPS

Terumo (OTCMKTS:TRUMY) posted its quarterly earnings results on Friday. The company reported $0.14 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.15 by ($0.01), reports. The company had revenue of $1.94 billion during the quarter, compared to analyst estimates of $1.82 billion. Terumo had a net margin of 12.35% and a return on equity of 9.39%.

Terumo Stock Up 6.1%

Shares of Terumo stock traded up $0.81 during trading on Friday, reaching $14.15. The company had a trading volume of 118,616 shares, compared to its average volume of 427,611. The company has a debt-to-equity ratio of 0.07, a quick ratio of 1.46 and a current ratio of 2.51. Terumo has a fifty-two week low of $12.51 and a fifty-two week high of $20.12. The firm’s fifty day moving average is $14.15 and its 200-day moving average is $15.92. The company has a market cap of $20.87 billion, a price-to-earnings ratio of 23.58 and a beta of 0.74.

About Terumo

Terumo Corporation (OTCMKTS: TRUMY) is a Japan-based medical technology company that develops, manufactures and markets a broad range of healthcare products for hospitals, clinics and blood centers. Its businesses encompass cardiovascular systems, general hospital products and blood management and cell technologies, supplying devices used in interventional and surgical procedures as well as everyday clinical care. Terumo sells consumables and capital equipment intended to support patient care across acute and ambulatory settings.

Key product categories include vascular access and interventional devices (such as guidewires, catheters and delivery systems), cardiac and cardiopulmonary surgical equipment, infusion therapy products (including infusion pumps and disposables), syringes and blood bags.